MRK - Merck & Co., Inc.
After hours:
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 113.11 |
| Open | 113.55 |
| Bid | 109.92 x 1000 |
| Ask | 110.13 x 800 |
| Day's Range | 109.28 - 113.72 |
| 52 Week Range | 83.05 - 119.65 |
| Volume | |
| Avg. Volume | 7,349,674 |
| Market Cap | 279.144B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 21.16 |
| EPS (TTM) | 5.20 |
| Earnings Date | Aug 01, 2023 |
| Forward Dividend & Yield | 2.92 (2.63%) |
| Ex-Dividend Date | Jun 14, 2023 |
| 1y Target Est | 124.42 |
Fair Value
Related Research
Yahoo Finance VideoMerck sues U.S. government over Medicare drug pricing negotiation
Merck is suing the U.S. government over a law that lets Medicare negotiate drug prices. Yahoo Finance health care reporter Anjalee Khemlani explains why Merck is upset over the law.
The Wall Street JournalMerck Challenges U.S. Government’s New Powers to Negotiate Drug Prices
The drugmaker filed a lawsuit saying Medicare’s drug-price negotiation program violates the company’s constitutional rights.
InvestopediaDow Jones Today: Index Higher on Bank Bounce
The Dow Jones Industrial Average finished the session essentially flat, with tech and financial stocks helping give the index a 0.03% boost.
BenzingaNovocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts
Zai Lab Limited (NASDAQ: ZLAB) and Novocure Limited (NASDAQ: NVCR) presented results from the phase 3 LUNAR trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies for non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology Annual Meeting. The LUNAR trial met its primary endpoint with a statistically significant and clinically meaningful 3-month improvement in median overall survival (OS) when TTFields therapy was added t
InvestopediaMerck Sues To Stop Medicare Drug Negotiation
Merck (MRK), the New Jersey-based maker of widely-used cancer treatment Keytruda, filed a lawsuit Tuesday in a federal court in Washington seeking to block the drug negotiation program, created by the Inflation Reduction Act of 2022, from going into effect in 2026.
- Reuters
UPDATE 5-Merck sues US government to halt Medicare drug price negotiation
Merck & Co sued the U.S. government on Tuesday, seeking to halt the Medicare drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution. This is the first attempt by a drugmaker to challenge the law, which the pharmaceutical industry says will result in a loss of profits that will force them to pull back on developing groundbreaking new treatments. The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for drugs paid for by Medicare, the government health plan for those age 65 and over.
ReutersMerck sues US government to halt Medicare drug price negotiation
Merck & Co said it sued the U.S. government on Tuesday, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution.
Business WireU.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
RAHWAY, N.J., June 06, 2023--U.S. FDA Approves New Indication for Merck’s PREVYMIS® for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
Business WireMerck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
RAHWAY, N.J., June 06, 2023--Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
- Reuters
UPDATE 1-Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid-stage trial, the companies reported on Monday. With this and earlier data, Moderna is considering seeking faster approval from regulators for the treatment, the company told investors after having presented the results at the American Society of Clinical Oncology meeting in Chicago. "Some of the residual uncertainty seems to be going away on that potential (option)," said Moderna President Stephen Hoge.
BenzingaModerna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced distant metastasis-free survival (DMFS) results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940) plus Keytruda for resected high-risk melanoma. The candidate is an investigational individualized neoantigen therapy. The companies recently announced the first presentation of the study's primary endpoint, recurrence-free survival, from the Phase 2 KEYNOTE-942/mRNA-4157-P201 trial in April 2023 at the American
ACCESSWIREModerna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA,
- Reuters
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, follow earlier promising data from the trial showing the customized mRNA vaccine given in combination with Merck's Keytruda cut the risk of death or recurrence of melanoma by 44% compared with Keytruda alone. The findings add to a growing body of evidence suggesting that mRNA technology, which rose to prominence during the COVID-19 pandemic, can be used to assemble personalized vaccines that train the immune system to attack the specific type of cancer cells in a patient's tumors.
Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
RAHWAY, N.J., June 03, 2023--KEYTRUDA Plus Chemo Before Surgery and as a Single Agent After Surgery Reduced Risk of EFS by 42% Vs Pre-Operative Chemo in Stage II, IIIA, IIIB NSCLC
Business WireKEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
RAHWAY, N.J. & KINGSTON, Ontario, June 03, 2023--KEYTRUDA Plus Chemo Significantly Improved Overall Survival Versus Chemo Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
Insider Monkey10 Stocks Jim Cramer Thinks Are Climbing In This Market
In this article, we will be looking at 10 stocks Cramer thinks are climbing in this market. To explore similar stocks, you can take a look at 5 Stocks Jim Cramer Thinks Are Climbing In This Market. “The Winners Make No Sense” On May 9, CNBC’s Mad Money host, Jim Cramer, dived into the current […]
Business WireFDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RAHWAY, N.J., June 01, 2023--FDA Approves LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC
The Wall Street JournalNew Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy
The shot won FDA approval as a new study finds a 14-percentage-point drop in vaccine confidence since the Covid pandemic.
InvestorPlace3 Innovative Growth Stocks to Buy for Next-Gen Profits
In a globally synchronized world, there are big opportunities across sectors. This has intensified competition as companies look to grab a share of the pie. It eventually boils down to the survival of the fittest. In the context of corporations, the innovation factor determines the “fittest.” Therefore, this column focuses on innovative growth stocks for future profits. It goes without saying that the basic screening criteria are to investigate companies with high investment in research and deve
Business WireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
RAHWAY, N.J. & NUTLEY, N.J., May 25, 2023--KEYTRUDA® Plus LENVIMA® Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Insider Monkey14 Best Biotech Stocks To Buy According To Hedge Funds
In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]
Insider Monkey14 Best Healthcare Dividend Stocks to Buy
In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]
InvestorPlace7 Stocks That Could Be the Next $2 Trillion-Dollar Companies
As someone who has been writing about stocks professionally for 18 years, I remember when Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN) and Apple (NASDAQ:AAPL) were the first companies with $1 trillion market capitalizations. There was a great deal of fascination with the milestones at the time. Subsequently, both overcame the $2 trillion mark, and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) has also joined the $1 trillion club. I guess it’s natural that the first companies to cross that huge $1 trilli
Business WireMerck Announces Third-Quarter 2023 Dividend
RAHWAY, N.J., May 23, 2023--Merck Announces Third-Quarter 2023 Dividend
